美国食品药品监督管理局（FDA）已正式批准默沙东动物保健旗下产品Numelvi™（Atinvicitinib片剂）用于犬类。该药物成为全球首个且唯一获批的第二代Janus激酶（JAK）抑制剂，专门用于控制由过敏性皮炎引起的瘙痒症状。
这一突破性疗法为患有过敏性皮炎的犬只提供了全新的治疗选择，通过靶向JAK信号通路有效缓解瘙痒不适，有望显著提升患病动物的生活质量。
美国食品药品监督管理局（FDA）已正式批准默沙东动物保健旗下产品Numelvi™（Atinvicitinib片剂）用于犬类。该药物成为全球首个且唯一获批的第二代Janus激酶（JAK）抑制剂，专门用于控制由过敏性皮炎引起的瘙痒症状。
这一突破性疗法为患有过敏性皮炎的犬只提供了全新的治疗选择，通过靶向JAK信号通路有效缓解瘙痒不适，有望显著提升患病动物的生活质量。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.